Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer

Gynecologic Oncology

Volumn 67, Issue 2, 1997, Pages 168-171

  Vallejos, Carlos ^a   Solidoro, Andres ^a   Gómez, Henry ^a   Castellano, Carlos ^a   Barriga, Oscar ^a   Galdos, Ricardo ^a   Casanova, Luis ^a   Otero, Jorge ^a   Rodriguez, Wuilbert ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IFOSFAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LAPAROTOMY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031281527     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4845     Document Type: Article

References (16)

1. Br Med J. 303:1991;884-893.
2. Decker D G, Fleming T R, Malkasian G D, Webb M J, Jefferies J A, Edmonson J H. Cyclophosphamide pluscis. Obstet Gynecol. 60:1982;481-487.
3. Omura G A, Bundy B N, Berek J S, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 7:1989;457-465.
4. J Clin Oncol. 9:1991;1668-1674.
5. Sutton G P, Blessing J A, Homesley H D, Berman M L, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 7:1989;1672-1676.
6. Markman M, Hakes T, Reichman B, Lewis J L, Rubin S, Jones W, Almadrones L, Pizzuto F, Hoskins W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cabcer: activity in platinum-resistant disease. J Clin Oncol. 10:1992;243-248.
7. Sorensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol. 56:1995;75-78.
8. Handbook for Reporting Results of Cancer Treatment. 1979.
9. Kaplan E L, Meier P. Non parametric estimation from incomplete observations. J Am Stat Soc. 53:1958;457-481.
10. Araujo C E, Cervellino J C, Pirisi C, Pannuzio O, Callegari J. Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer. J Surg Oncol. 46:1991;198-202.
11. Lund B, Hansen M, Hansen O P, Hansen H H. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol. 8:1990;1226-1230.
12. Conte P F, Bruzzone M, Chiara S, Sertoli M R, Daga M G, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L, Carnino F, Cottini M, Mosetti C, Guercio E, Gatti M, Siliquini P N, Prelato M L, Durando C, Giaccone G, Calciati A, Farinini D, Centonze M, Rugiati S, Parodi G, Messineo M, Storace A, Bernardini G, Misurale F, Alessandri S, Casini M, Ragni N, Foglia G, Bentivoglio G, Pescetto G. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicine, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol. 4:1986;965-971.
13. Omura G A, Bleesing J A, Ehrlich C E, Miller A, Yordan E, Creasman W T, Homesley H D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 57:1985;1725-1730.
14. Goren M P, Wright R, Pratt C. Dechorethylation of ifosfamide and neurotoxicity. Lancet. 335:1990;175-176.
15. Cerny T, Kupfer A. The enigma of ifosfamide encephalopathy. Ann Oncol. 3:1992;679-681.
16. Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol. 51:1993;104-108.